The global non-small cell lung carcinoma (NSCLC) market is expected to garner a market value of USD 8.25 Billion in 2023 and is expected to accumulate a market value of USD 21.40 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033. The growth of the non-small cell lung carcinoma (NSCLC) market can be attributed to the rising prevalence of NSCLC across the globe due to increasing air pollution and smoking habits amongst people. The market for non-small cell lung carcinoma (NSCLC) registered a CAGR of 7.3% in the historical period 2017 to 2022.
The presence of a strong pipeline for non-small cell lung carcinoma is projected to propel the growth over the coming years. For instance, fruquintinib (HMPL-013), a drug developed to treat advanced non-small cell lung carcinoma is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, the development of such advanced treatments is expected to drive the market during the forecast period.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | USD 7.5 Billion |
| Expected Market Value (2023) | USD 8.25 Billion |
| Anticipated Forecast Value (2033) | USD 21.4 Billion |
| Projected Growth Rate (2023 to 2033) | 10% CAGR |
According to market research and competitive intelligence provider Future Market Insights- the market for non-small cell lung carcinoma (NSCLC) reflected a value of 7.3% during the historical period, 2018 to 2022.
Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to clinicaltrials.gov in July 2021, it was observed that more than 200 interventional studies were halted from March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products.
According to an article published in September 2020 titled The impact of the COVID-19 pandemic on lung cancer patients, at the Fifth Affiliated Hospital of Sun Yat-sen University, around 95 patients out of 161 had delayed their return visits in April 2020, and 47 cases finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments. Thus, the market for non-small cell lung carcinoma (NSCLC) is expected to register a CAGR of 10% in the forecast period 2023 to 2033.
Smoking and tobacco consumption increasing the number of patients suffering from non-small cell lung carcinoma
The American Cancer Society estimates that lung cancer is one of the highest death-causing diseases in the world. Covid-19 significantly affected non-small cell lung cancer-related clinical trials across the world. However, cancer care and maintaining high standards of diagnosis and treatment have been the major priorities of national healthcare bodies and international healthcare systems worldwide.
The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients.
Approvals of Medication for Lung Carcinoma Propelling Market Growth
As per the statistics provided by the World Health Organization (WHO) updates from February 2022, 2.2 Billion patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung carcinoma patients resulted in the high demand for treating the patients.
Recent approvals of new drugs are expected to accelerate market growth during the forecast period. For instance, In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the USA. Additionally, in October 2021, Ventana Medical Systems, Inc. received United States of America FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.
Longer Duration for approval of Medication hampering Growth of Market
The expensive nature of research and development of medication to treat patients is derailing the progress of the market. In addition, the financial burden added by the COVID-19 pandemic is playing a key role in hindering the growth of the market. Furthermore, the time taken for approval of drugs along with certain medications not being approved in spite of being in the clinical trial phase for a longer duration is hampering the overall growth of the non-small cell lung carcinoma market.
Launch of new drugs creating Favorable treatment for non-small cell lung carcinoma in North America
North America is expected to maintain its dominance during the forecast period and is one of the most lucrative regions for the NSCLC market. This is due to the presence of a strong pipeline and research activities undertaken by various industry players and academic institutions.
Thus, North America is expected to account for the largest share of all the regions in 2023. This is attributed to the entry of newer drugs, high investment by players, acceptance of costly drugs, and increased government funding for research and development activities. Owing to the aforementioned reasons, North America is expected to possess a 40% market share for the non-cell lung carcinoma market in 2023.
Less stringent regulator framework opening doors for medication development in the Asia Pacific
Asia Pacific is expected to be the second largest contributor in 2023 for the non-small lung cell carcinoma market. This is owing to the presence of less stringent regulatory procedures for approval and a large patient pool. Japan and China are expected to contribute the highest to the Asia Pacific region due to the availability of advanced drugs, a developed economy, and a large patient pool.
Pricing pressure by the governments of European countries is likely to affect the market negatively during the forecast period. For instance, in October 2016, the National Institute for Health and Care Excellence (NICE) disapproved funding for Opdivo, as it did not meet the required cost-to-benefit ratio. Thus, Asia Pacific is expected to possess a 35% market share for the non-small cell lung carcinoma market.
Key players in the market are non-small cell lung carcinoma market AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline plc, Novartis, Pfizer Inc, Roche Holding AG, Sun Pharmaceutical Industries Ltd.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 8.25 Billion |
| Market Value in 2033 | USD 21.4 Billion |
| Growth Rate | CAGR of 10% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia & Pacific; East Asia; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Pfizer Inc.; AstraZeneca Plc.; F. Hoffmann-La Roche Ltd.; Eli Lily and Company; Boehringer Ingelheim GmbH; Novartis AG; Bristol-Myers Squibb Company; Merck & Co. Inc.; Celgene Corp.; Sun Pharmaceutical Industries Ltd. |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia & Pacific Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 19: South Asia & Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 20: South Asia & Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 27: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 28: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Europe Market Attractiveness by Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 79: Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia & Pacific Market Value (US$ Million) by Type, 2023 to 2033
Figure 82: South Asia & Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 83: South Asia & Pacific Market Value (US$ Million) by End User, 2023 to 2033
Figure 84: South Asia & Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia & Pacific Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 89: South Asia & Pacific Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 90: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 91: South Asia & Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 92: South Asia & Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 93: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 94: South Asia & Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: South Asia & Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: South Asia & Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: South Asia & Pacific Market Attractiveness by Type, 2023 to 2033
Figure 98: South Asia & Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 99: South Asia & Pacific Market Attractiveness by End User, 2023 to 2033
Figure 100: South Asia & Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Type, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Type, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 119: East Asia Market Attractiveness by End User, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: MEA Market Value (US$ Million) by Type, 2023 to 2033
Figure 122: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 123: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 129: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 131: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 134: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 137: MEA Market Attractiveness by Type, 2023 to 2033
Figure 138: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 139: MEA Market Attractiveness by End User, 2023 to 2033
Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
From 2018 to 2022, the non-small cell lung carcinoma (NSCLC) market grew at a CAGR of 7.3%
The global non-small cell lung carcinoma (NSCLC) market is expected to grow with a 10% CAGR from 2023 to 2033.
As of 2033, the non-small cell lung carcinoma (NSCLC) market is expected to reach USD 21.40 Billion
North America is expected to possess 40% market share for non-small cell lung carcinoma (NSCLC) market in North America.
Asia Pacific is expected to possess 35% market share for non-small cell lung carcinoma market.
Explore Similar Insights
Non-Small Cell Lung Carcinoma (NSCLC) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
